Antinociceptive activity in Albino Swiss mouse assessed as inhibition of acetic acid-induced writhing response at 0.1 ED50, ip administered 60 mins prior to test measured for 10 mins
Inhibition of amphetamine-induced hyperlocomotion in Albino Swiss mouse at 0.1 ED50, ip administered 60 mins prior to test measured for 30 mins by photoresistor actometer analysis
Toxicity in Albino Swiss mouse assessed as inhibition of spontaneous locomotor activity at 0.1 ED50, ip administered 60 mins before test measured for 30 mins by photoresistor actometer analysis
Inhibition of 5-HTP-induced head twitch response in Albino Swiss mouse at 0.1 ED50, ip administered 60 mins before 5-HTP injection relative to untreated control
Antinociceptive activity in Albino Swiss mouse assessed as inhibition of acetic acid-induced writhing response at 0.025 to 0.05 ED50, ip administered 60 mins prior to test measured for 10 mins
Antinociceptive activity in Albino Swiss mouse assessed as inhibition of acetic acid-induced writhing response at 0.05 ED50, ip administered 60 mins prior to test measured for 10 mins in presence of opioid receptor antagonist naloxone
Anticonvulsant activity in Albino Swiss mouse assessed as protection against pentetrazol-induced tonic seizure at 0.1 ED50, ip administered 60 mins prior to test relative to untreated control
Protection against pentetrazol-induced mortality in Albino Swiss mouse at 0.1 ED50, ip administered 60 mins prior to test relative to untreated control
Anticonvulsant activity in Albino Swiss mouse assessed as protection against pentetrazol-induced clonic seizure at 0.1 ED50, ip administered 60 mins prior to test relative to untreated control